Navigation Links
Pharma Industry Unites With Academia to Tackle Ongoing Problem
Date:10/28/2011

LONDON, October 28, 2011 /PRNewswire/ --

Leading academic and industry specialists to meet in Amsterdam next February to discuss the challenges that could see R&D grind to a halt and the newest ways to tackle them

Selecting and screening the correct polymorphs and ensuring the characterisation of the co-crystals in the most efficient and effective way has never been more vital. According to George Tranter from Chiralabs, "Crystallisation is one of the biggest problems of the pharmaceutical industry".

The 8th Annual Polymorphism and Crystallisation speaker panel will be dedicated to presenting the cutting edge technologies and techniques of getting the pharmaceutical product to the market whilst overcoming the problems of polymorphism.

According to an Engineer article "Co-crystallisation could speed up drug production" (5th September), scientists have started seeking to understand the science behind this process. However, co-crystallisation requires particular attention to considerations like availability and quality of drugs, waste streams generated and batch performance. Pharma IQ's Polymorphism and Crystallisation speakers will provide an insight into these issues live only on 28th and 29th February in Amsterdam. Case studies will be presented by the likes of Eli Lily, UCB Pharma and Novartis-MIT Centre for Continuous Manufacturing, and a fantastic interactive workshop will be run by an EPO representative.

Pharma IQ's summit will be dedicated to delivering cutting edge insights into areas such as:

  • Best timing and depth for a polymorphic screen during pharmaceutical development
  • Characterisation of co-crystals and selection of tools for correct characterisation tests
  • Polymorphic scale up
  • Application of PAT and QbD in pharm
    '/>"/>

SOURCE Pharma IQ
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results on November 3, 2011
2. Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance
3. ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline
4. ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
5. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Expansion of Oncology Programs for Its Clients
6. Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate
7. Innovative Pharmacy Leader Jeanne Ann Stasny Joins Diplomat Specialty Pharmacy as Vice President of Pharmacy Services
8. Pharmaceutical Industry Leaders to Tackle Groundbreaking Challenges, Opportunities for Pharma & Biotech at Elite Event
9. Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals
10. Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - October 2011
11. Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Covance Inc. (NYSE: CVD ) today reported ... Net revenue was $639 million, representing 8.0% growth from ... the company reported earnings of $0.29 per diluted share ... earnings per diluted share of $0.95, up 21.5% over ... asset impairment charges totaling $52.6 million, or $0.61 per ...
(Date:7/29/2014)... , July 29, 2014 New high priced ... Part D by a projected $2.9 to $5.8 billion ... actuarial firm Milliman released today by the Pharmaceutical Care ... premiums could increase by as much as 8.6 percent ... drugs, including Sovaldi and Olysio. The study ...
(Date:7/29/2014)... SPRINGS, Colo. , July 29, 2014 ... catheter (MARC) which could allow physicians to see and ... may hold promise, according to study authors who released ... (SNIS) 11 th Annual Meeting in ... stand to advance the field of neurointervention, a specialty ...
Breaking Medicine Technology:Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3
(Date:7/30/2014)... (PRWEB) July 30, 2014 Neil Haley, the ... Vi Millionaire GJ Reynolds to find out about what is ... create the best brand. , Reynolds is an original founding ... Star Ambassador, Vi Millionaire, and CEO of Simply G Media. ... Warrior Within You!" and holds the distinction of completing the ...
(Date:7/30/2014)... 2014 Pain Free Living web: ... for pain relief and improved performance. This new magnetic ... in a silicone core that is sheathed in nylon ... is embedded with scalar energy and Schumann frequency thus ... Living has 12 years experience developing magnetic bracelets. We ...
(Date:7/29/2014)... Cucamonga, CA (PRWEB) July 29, 2014 Paul ... Ways to Make More Money in 30 Days” E-book. The ... anyone can use to make extra cash. Examples include downloading ... utilizing unique free websites that help people monetize the assets ... and even unused items they can find in their garage. ...
(Date:7/29/2014)... California (PRWEB) July 29, 2014 ... to senior communities with focus on Brain Fitness ... Living in Ventura. Brain Fitness Program Director Tee ... to Aegis Memory Care unit and the Assisted ... sessions. Aegis Life Enrichment Director Christy Rozsa and ...
(Date:7/29/2014)... Daily Gossip indicates that the new method can ... that hemorrhoids commonly causes. The new method was developed ... , The author of H Miracle reveals that ... such as itching, burning, pain and swelling, as well ... Miracle by visiting the official website at: http://www.dailygossip.org/cure-hemorrhoids-in-48-hours-review-6851 ...
Breaking Medicine News(10 mins):Health News:Entrepreneur and Vi Millioniare GJ Reynolds Discusses How to Improve Your Brand on the Simply G Radio Show, a Division of the Simply G Media Network 2Health News:Superior Magnetics Released New Magnetic Sports Bracelet for Pain 2Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 4Health News:H Miracle Review Exposes Natural Method to Cure Hemorrhoids 2
... , MONDAY, Jan.3 (HealthDay News) -- Two drugs ... may change the way the brain reacts to seeing someone ... how they cut cravings. Bupropion (Wellbutrin, Zyban) is prescribed ... it has not been clear how the drug does this. ...
... MONDAY, Jan. 3 (HealthDay News) People at higher risk ... new study findings show. Researchers at Washington University School ... U.S. alcoholism surveys conducted in 1991-1992 and 2001-2002. According to ... family history of alcoholism were 49 percent more likely to ...
... 15 years the U.S has seen a sharp increase in ... and 37 weeks, gestation. This is approximately 400,000 children each ... late-preterm infants are treated the same as full-term infants since ... is showing that this can be detrimental to a late-preterm ...
... Total Occlusion Summit and Left Main Coronary Interventions ... research findings and new developments in therapeutic procedures ... chronic total coronary occlusions and left main coronary ... When and why to open a chronic ...
... group to it at a specific site, a protein arrests ... research team led by scientists at The University of Texas ... Nature Cell Biology . In addition to highlighting ... deactivation of the enzyme called EZH2 is necessary for the ...
... Rockville, Md., January 3, 2011 For the first ... and appearance of prescription medication labels to reflect how ... on a national level. These labels can vary significantly ... to convey critical information for the safe use of ...
Cached Medicine News:Health News:Studies Decipher How Anti-Smoking Drugs Work 2Health News:Family History of Alcoholism May Raise Obesity Risk 2Health News:Care of late-preterm preemies may be insufficient 2Health News:Care of late-preterm preemies may be insufficient 3Health News:Protein wields phosphate group to inhibit cancer metastasis 2Health News:Universal standards proposed for prescription container labels to help reduce medication misuse 2Health News:Universal standards proposed for prescription container labels to help reduce medication misuse 3
Khosla Precision and Quality in Medical and Surgical Products....
...
...
To enter, dissect, elevate and smooth the flap. Combined features of Spatula, Dissector and Forceps. - Also available in Titanium...
Medicine Products: